To describe the prevalence and clinical determinants of apathy in elderly nondemented patients with Parkinson's disease (PD) and their relationship to quality of life (QoL).
Methods:
A total of 106 nondemented elderly patients with PD were examined using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Starkstein Apathy Scale, Hospital Anxiety and Depression Scale, Beck Depression Inventory-II, and 39-item Parkinson’s disease quality of life questionnaire.
Results:
Apathy was present in 54% of the studied population. Factors associated with apathy were higher depression scores and a lower daily levodopa equivalent dose. Longer disease duration, higher motor MDS-UPDRS subscore, and higher depression and anxiety scores, but not apathy, were found to be associated with worse QoL.
Conclusions:
Although apathy does not seem to be an independent predictor of worse QoL specifically in elderly patients with PD, it remains very relevant, as its presence increases caregiver burden. Both depression and potential dopaminergic treatment underdosing can be properly managed, thus potentially reducing the prevalence and severity of apathy in a proportion of the apathetic patients with PD.
Benito-LeonJCuboECoronellC. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov Disord. 2012;27(2):211–218.
2.
OguruMTachibanaHTodaKOkudaBOkaN. Apathy and depression in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2010;23(1):35–41.
3.
DrijgersRLDujardinKReijndersJSDefebvreLLeentjensAF. Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat Discord. 2010;16(10):656–660.
4.
StarksteinSEPetraccaGChemerinskiEKremerJ. Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry. 2001;158(6):872–877.
5.
BrodatyHSachdevPSWithallAAltendorfAValenzuelaMJLorentzL. Frequency and clinical, neuropsychological and neuroimaging correlates of apathyfollowing stroke—the Sydney Stroke Study. Psychol Med. 2005;35(12):1707–1716.
6.
MarinRS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243–254.
7.
RobertPOnyikeCULeentjensAFG. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry. 2009;24(2):98–104.
8.
CuboEBenito-LeonJCoronellC. Clinical correlates of apathy in patients recently diagnosed with Parkinson’s disease: the ANIMO Study. Neuroepidemiology. 2012;38(1):48–55.
9.
AarslandDBronnickKAlvesG. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928–930.
10.
CzerneckiVSchupbachMYaiciS. Apathy following deep brain stimulation in Parkinson’s disease: a dopamine responsive symptom. Mov Disord. 2008;23(7):964–969.
11.
ChaudhuriKRSchapiraAH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.
12.
ThoboisSArdouinCLhommeeE. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain. 2010;133(pt 4):1111–1127.
13.
Kirsch-DarrowLMarsiskeMOkunMSBauerRBowersD. Apathy and depression: separate factors in Parkinson’s disease. J Int Neuropsych Soc. 2011;17(6):1058–1066.
14.
Kirsch-DarrowLFernandezHFMarsiskeMOkunMDBowersD. Dissociating apathy and depression in Parkinson disease. Neurology. 2006;67(1):33–38.
15.
Ziropadja Lj, Stefanova E, Petrovic M, Stojkovic T, Kostic VS. Apathy and depression in Parkinson’s disease: the Belgrade PD study report. Parkinsonism Relat Disord. 2012;18(4):339–342.
16.
DujardinKSockeelPDelliauxMDesteeADefebvreL. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord. 2009;24(16):2391–2397.
17.
MorettiRTorrePAntonelloRM. Apathy: a complex symptom specific to the clinical pattern of presentation of Parkinson’s disease?Am J Alzheimers Dis Other Demen. 2012;27(3):196–201.
18.
RobertPHBerrCVolteauM.; PréAL study Group. Importance of lack of interest in patients with mild cognitive impairment. Am J Geriat Psychiat. 2008;16(9):770–776.
19.
HarrisEMcNamaraPDursoR. Apathy in Parkinson’s disease as a function of side of onset. J Geriatr Psych Neur. 2013;26(2):95–104.
20.
HughesTARossHFMindhamRHSpokesEG. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand. 2004;110(2):118–123.
21.
McDowellIHillGLindsayJ. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J. 1994;150(6):899–913.
22.
BrodatyHAltendorfAWithallASachdevP. Do people become more apathetic as they grow older? A longitudinal study in healthy individuals. Int Psychogeriatr. 2010;22(3):426–436.
23.
LeroiIAhearnDJAndrewsMMcDonaldKByrneEJBurnsA. Behavioural disorders, disability and quality of life in Parkinson's disease. Age Ageing. 2011;40(5):614–621.
24.
HughesAJDanielSEKilfordLLeesAJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosur Psychiatry. 1992;55(3):181–184.
25.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
26.
GoetzCGTilleyBCShaftmanSR. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170.
27.
HoehnMMYahrMD. Parkinsonism onset progression and mortality. Neurology. 1967;17(5):427–442.
28.
TomlinsonCLStoweRPatelSRickCGrayRClarkeCE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–2653.
29.
SkorvanekMKosutzkaZValkovicP. Validation of Slovak version of the Movement Disorder Society - Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). Cesk Slov Neurol N. 2013.76/109(4):463–468
30.
LeroiIHarbishettarVAndrewsMMcDonaldKByrneEJBurnsA. Carer burden in apathy and impulse control disorder in Parkinson’s disease. Int J Geriatr Psychiatry. 2012;27(2):160–166.
31.
StarksteinSEMaybergHSPreziosiTAndrezejewskiPLeiguardaRRobinsonRG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsych Clin Neurosci. 1992;4(2):134–139.
32.
BeckATSteerRABallRRanieriW. Comparison of beck depression inventories-IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588–597.
33.
ZigmondASSnaithRP. The hospital anxiety and depression scale. Acta Psychiat Scand. 1983;67(6):361–370.
34.
PetoVJenkinsonCFitzpatrickRGreenhallR. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3):241–248.
35.
MarinusJRamakerCvan HiltenJJStiggelboutAM. Health related quality of life in Parkinson’s disease: a systematic review of disease specific instruments. J Neurol Neurosur Psychiatry. 2002;72(2):241–248.
36.
Kirsch-DarrowLZahodneLBHassC. How cautious should we be when assessing apathy with the Unified Parkinson’s Disease Rating Scale?Mov Disord. 2009;24(5):684–688.
37.
PedersenKFLarsenJPAlvesGAarslandD. Prevalence and clinical correlates of apathy in Parkinson’s disease: a community based study. Parkinsonism Relat Disord. 2009;15(4):295–299.
38.
StarksteinSEBrockmanS. Apathy and Parkinson’s disease. Curr Treat Options Neurol. 2011;13(3):267–273.
39.
LevyRDuboisB. Apathy and the functional anatomy of the prefrontal cortex—basal ganglia circuits. Cereb Cortex. 2006;16(7):916–928.
40.
RobbinsTWEverittBJ. Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol. 1996;6(2):228–236.
41.
SchultzWDayanPMontaguePR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593–1599.
42.
YamanishiTTachibanaHOguruM. Anxiety and depression in patients with Parkinson’s disease. Intern Med. 2013;52(5):539–545.
